UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of
Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit
In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.